Scienture Holdings, Inc. 10-K

ITEM 8. FINANCIAL STATEMENTS REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Scienture Holdings, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Scienture Holdings, Inc. (the Company) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the each of the years ended then ended, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. Emphasis of a matter – Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. Business combination - Fair value of acquired intangible assets Description of the matter As discussed in Note 1 and Note 3 to the consolidated financial statements, on July 25, 2024, the Company acquired Scienture, Inc. in a transaction accounted for as a business combination. As a result of the transaction, the Company recognized acquired technology associated with the generation of future income. The acquisition-date fair value of the acquired technology was $76.4 million. We identified the determination of the fair values of the identifiable intangible assets as a critical audit matter. The Company’s estimation of the acquisition date fair values of certain identifiable intangible assets is complex, requires management’s judgment and involves the use of significant estimates and assumptions, including selection of the appropriate valuation methodology, revenue growth rates, forecasted expenses, royalty rates, and discount rates. Auditing these elements involved especially challenging and subjective auditor judgment due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or knowledge needed. How We Addressed the Matter in our Audit The following are the primary procedures we performed to address this critical audit matter: ● Assessing the reasonableness of projected revenue growth rates and forecasted expenses through: (i) evaluating historical performance of the acquired entity, and (ii) assessing financial projections against market trends, industry metrics and peer-group/guideline companies. ● Utilizing personnel with specialized knowledge and skill with valuation to assist in: (i) assessing the reasonableness of royalty rates and discount rates incorporated into the various valuation models, and (ii) assessing the appropriateness of various valuation models utilized by management to determine the fair values of the intangible assets. /s/ CM3 Advisory We have served as the Company’s auditor since 2023 San Diego, California March 26, 2025 84 Table of Contents Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Consolidated Balance Sheets December 31, 2024 and 2023 2024 2023 December 31, 2024 2023 ASSETS Current assets: Cash $ 308,096 $ 314 Accounts receivable, net 11,106 - Inventory - 968 Prepaid expenses 4,560 50,724 Notes receivable - related party 1,300,000 1,300,000 Other receivables 4,138,770 1,224,702 Deferred offering costs 534,800 - Current assets of discontinued operations 8,145 176,355 Total current assets 6,305,477 2,753,063 Property, plant and equipment, net 17,500 7,500 Deposits 22,039 10,531 Intangible assets, net 76,400,000 - Goodwill 21,372,960 - Operating lease right-of-use assets 201,433 191,216 Deferred tax asset 534,396 - Noncurrent assets of discontinued operations - 9,570,603 Total assets $ 104,853,805 $ 12,532,913 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable $ 2,898,683 $ 1,463,014 Accrued liabilities 1,313,731 160,214 Other current liabilities 5,441 67,831 Loan payable, related party 415,000 - Convertible note, net of debt discount - current portion 2,285,423 Contingent funding liabilities - 1,246,346 Operating lease liability - current 63,334 32,595 Warrant liability 919,935 736,953 Current liabilities of discontinued operations 5,346 7,849,402 Total current liabilities 7,906,893 11,556,355 Convertible notes, net of debt discount 612,275 - Derivative liability 2,296,834 - Operating lease liability - net of current portion 156,469 176,909 Development agreement liability 1,285,000 - Deferred tax liability 13,524,213 Noncurrent liabilities of discontinued operations - 257,296 Total liabilities 25,781,684 11,990,560 Commitments and contingencies (Note 15) - - Stockholders’ equity (deficit): Series A preferred stock, $ 0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and 2023, all respectively - - Series B preferred stock, $ 0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both December 31, 2024 and 2023 - - Series C preferred stock, $ 0.00001 par value; 1,000 shares authorized; 0 and 290 shares issued and outstanding as of December 31, 2024 and 2023, respectively - - Series X preferred stock, $ 0.00001 par value; 9,211,246 shares authorized; 0 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively - - Preferred stock, value - - Common stock, $ 0.00001 par value; 100,000,000 shares authorized; 8,750,582 and 905,008 shares issued and outstanding as of December 31, 2024 and 2023, respectively 87 9 Additional paid-in capital 118,111,007 33,788,284 Accumulated deficit ( 39,038,973 ) ( 33,245,940 ) Total stockholders’ equity 79,072,121 542,353 Total liabilities and stockholders’ equity $ 104,853,805 $ 12,532,913 The accompanying notes are an integral part of the unaudited consolidated financial statements. 85 Table of Contents Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Consolidated Statements Of Operations Years Ended December 31, 2024 and 2023 2024 2023 Year Ended December 31, 2024 2023 Revenues $ 136,643 $ 1,363,830 Cost of sales 130,638 1,314,800 Gross profit 6,005 49,030 Operating expenses: Wage and salary expense 2,111,066 626,547 Professional fees 1,458,332 875,136 Accounting and legal expense 1,807,041 1,506,881 Technology expense 416,311 100,280 General and administrative 6,677,580 1,336,637 Research and development 2,236,690 - Total operating expenses 14,707,020 4,445,481 Operating loss ( 14,701,015 ) ( 4,396,451 ) Non-operating income (expense): Change in fair value of warrant liability ( 182,982 ) ( 148,420 ) Change in fair value of derivative liability 180,383 - Impairment of investment ( 2,500,000 ) - Interest income 135,337 4,198 Loss on disposal of asset ( 374,968 ) ( 2,798,968 ) Interest expense ( 1,335,631 ) ( 1,143,223 ) Total non-operating expense ( 4,077,861 ) ( 4,086,413 ) Net loss from continuing operations ( 18,778,876 ) ( 8,482,864 ) Benefit / (provision) for income taxes 534,396 - Net loss from continuing operations, net of tax ( 18,244,480 ) ( 8,482,864 ) Net income (loss) from discontinued operations, net of tax 27,310,278 ( 9,360,710 ) Net income (loss) $ 9,065,798 $ ( 17,843,574 ) Net loss per common share from continuing operations Basic $ ( 5.41 ) $ ( 11.10 ) Diluted $ ( 5.41 ) $ ( 11.10 ) Net income (loss) per common share from discontinued operations Basic $ 8.09 $ ( 12.25 ) Diluted $ 7.47 $ ( 3.93 ) Net income (loss) per common share Basic $ 2.69 $ ( 23.35 ) Diluted $ 2.48 $ ( 23.35 ) Weighted average common shares outstanding Basic 3,375,325 764,058 Diluted 3,653,609 2,381,443 The accompanying notes are an integral part of the unaudited consolidated financial statements. 86 Table of Contents Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Consolidated Statements of Changes in Stockholders’ Equity Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Capital Deficit Subsidiaries Equity Series A Series B Series C Series X Common Additional Non-controlling Total Preferred Stock Preferred Stock Preferred Stock Preferred Stock Stock Paid-in Accumulated Interests in Stockholders’ Shares Amount Shares Amount Shares Amount Shares Amount Shares Amount Capital Deficit Subsidiaries Equity Balances at December 31, 2022 - $ - - $ - - $ - - $ - 626,247 $ 6 $ 20,482,666 $ ( 19,719,536 ) $ ( 420,269 ) $ 342,867 Common stock issued for services - - - - - - - - 38,480 - 257,772 - - 257,772 Warrants exercised for cash - - - - - - - - 41,911 1 1,621 - - 1,622 Options expense - - - - - - - - - - 29,738 - - 29,738 Reverse split rounding adjustment - - - - - - - - 21,929 - - - - - Disposition of assets - - - - - - - - - - - 4,317,170 420,269 4,737,439 Shares issued pursuant to merger agreement - - 15,759 - - - - - 136,441 1 12,500,088 - - 12,500,089 Shares issued pursuant to securities purchase - - - - 290 - - - 40,000 1 516,399 - - 516,400 Net loss - - - - - - - - - - - ( 17,843,574 ) - ( 17,843,574 ) Balances at December 31, 2023 - - 15,759 - 290 - - - 905,008 9 33,788,284 ( 33,245,940 ) - 542,353 Balance - - 15,759 - 290 - - - 905,008 9 33,788,284 ( 33,245,940 ) - 542,353 Common stock issued for services - - - - - - - - 490,698 5 4,598,289 - - 4,598,294 Conversion of Series C preferred stock into common stock - - - - ( 290 ) - - - 52,158 1 ( 1 ) - - - Issuance of shares pursuant to Merger - - - - - - 6,826,753 68 291,536 3 78,646,113 - - 78,646,184 Conversion of Series X preferred stock into common stock - - - - - - ( 6,826,753 ) ( 68 ) 6,826,753 68 - - - - Equity line of commitment shares issued - - - - - - - - 70,000 1 534,799 - - 534,800 Issuance of common shares in connection with convertible note - - - - - - - - 55,000 1 420,199 - - 420,200 Warrants issued with convertible note - - - - - - - - - - 71,332 - - 71,332 Options exercised for common shares - - - - - - - - 2,371 - 9,840 - - 9,840 Warrants exercised for cash - - - - - - - - 57,058 - 16,567 - - 16,567 Options expense - - - - - - - - - - 25,584 - - 25,584 Cash dividends paid ($ 8 per share) - - - - - - - - - - - ( 12,671,072 ) - ( 12,671,072 ) Cash dividends paid ($ 1.50 per share) - - - - - - - - - - - ( 2,187,759 ) - ( 2,187,759 ) Net income - - - - - - - - - - - 9,065,798 - 9,065,798 Net income (loss) - - - - - - - - - - - 9,065,798 - 9,065,798 Balances at December 31, 2024 - $ - 15,759 $ - - $ - - $ - 8,750,582 $ 87 $ 118,111,007 $ ( 39,038,973 ) $ - $ 79,072,121 Balance - $ - 15,759 $ - - $ - - $ - 8,750,582 $ 87 $ 118,111,007 $ ( 39,038,973 ) $ - $ 79,072,121 The accompanying notes are an integral part of the unaudited consolidated financial statements. 87 Table of Contents Scienture Holdings, Inc. formerly TRxADE HEALTH, INC. Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023 2024 2023 Year Ended December 31, 2024 2023 Cash flows from operating activities: Net loss from continuing operations $ ( 18,778,876 ) $ ( 8,482,864 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense 2,000 19,375 Change in fair value of warrant liability 182,982 148,420 Change in fair value of derivative liability ( 180,383 ) - Options expense 25,584 29,738 Common stock issued for services 4,598,294 257,772 Impairment of investment 2,500,000 - Amortization of debt discount 912,447 - Amortization of right-of-use assets 51,361 215,665 Amortization of intangible assets - 814,790 Goodwill impairment - 5,129,115 Changes in operating assets and liabilities: Accounts receivable, net ( 11,106 ) ( 293,784 ) Prepaid expenses and deposits 34,656 38,367 Inventory 968 4,232,947 Other receivables ( 2,914,068 ) ( 254,924 ) Lease liability ( 51,587 ) ( 228,470 ) Accounts payable 448,572 1,607,625 Accrued liabilities ( 44,616 ) 58,692 Purchase price payable - 350,000 Current liabilities ( 62,390 ) 2,794 Net cash (used in) provided by operating activities from continuing operations ( 13,286,163 ) 3,645,257 Net cash used in operating activities from discontinued operations ( 979,075 ) ( 5,870,449 ) Net cash used in operating activities ( 14,265,239 ) ( 2,225,192 ) Cash flows from investing activities: Cash received in acquisition 132,976 - Acquisition of property and equipment ( 12,000 ) - Investment in securities ( 2,500,000 ) - Funds acquired through acquisitions - ( 344,454 ) Net cash used in investing activities from continuing operations ( 2,379,024 ) ( 344,454 ) Net cash provided by investing activities from discontinued operations 29,931,815 68,737 Net cash provided by (used in) investing activities 27,552,791 ( 275,717 ) Cash flows from financing activities: Repayment of contingent liability ( 1,246,346 ) ( 1,043,107 ) Proceeds from issuance from debt - 400,000 Repayment of debt - ( 150,000 ) Proceeds from loan payable, related party 150,000 - Proceeds from issuance of convertible notes, net of issuance costs 2,954,000 - Cash dividends paid ( 14,858,831 ) - Proceeds from sale of future revenue - 2,181,417 Proceeds from exercise of warrants 16,567 1,622 Proceeds from securities purchase agreement - 516,400 Proceeds from exercise of options 9,840 - Net cash (used in) provided by financing activities from continuing operations ( 12,974,770 ) 1,906,332 Net cash used in financing activities from discontinued operations ( 5,000 ) ( 500,000 ) Net cash (used in) provided by financing activities ( 12,979,770 ) 1,406,332 Net change in cash 307,782 ( 1,094,577 ) Cash at beginning of year 314 1,094,891 Cash at end of year $ 308,096 $ 314 Supplemental disclosure of cash flow information: Cash paid for interest $ - $ 733,694 Cash paid for taxes $ - $ - Supplemental disclosure of non-cash investing and financing activities: Issuance of shares pursuant to Merger $ 78,646,184 $ - Assets acquired in connection with Merger $ 194,554 $ - Liabilities assumed in connection with Merger $ 5,797,117 $ - Insurance premium financed $ 198,245 $ 306,152 Warrants issued with convertible note $ 71,332 $ - Issuance of common shares in connection with converible debenture $ 420,200 $ - Equity line of commitment shares issued as offering costs $ 534,800 $ - Derivative liability recognized in connection with issuance of convertible note $ 2,477,217 $ - Note issued as SOSRx contribution $ - $ 500,000 Disposition of assets, related party $ - $ 492,030 Issuance of note receivable $ - $ 1,300,000 The accompanying notes are an integral part of the unaudited consolidated financial statements. 88 Table of Contents NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Overview On September 20, 2024, the Company filed with the Secretary of State of the State of Delaware an amendment to its Second Amended and Restated Certificate of Incorporation to change the legal name of the Company from “TRxADE HEALTH, Inc.” to “Scienture Holdings, Inc.” The Company owned, as of December 31, 2024, 100 % of Softell Inc. (f/k/a Trxade Inc.), Integra Pharma Solutions, LLC, and Scienture, LLC (f/k/a Scienture, Inc.). On October 4, 2024, the Company and Softell Inc. (f/k/a Trxade Inc.) (“Softell”) entered into an Assignment and Assumption of Membership Interests (the “IPS Assignment Agreement”), pursuant to which the Company transferred, and Softell accepted, 100 % of the membership interests of Integra Pharma Solutions, LLC (“IPS”). As a result, IPS is now a wholly-owned subsidiary of Softell. During the year ended December 31, 2023 and a portion of the quarter ended March 31, 2024, Softell, operated a web-based market platform that enabled commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Softell’s current primary operations are conducted through IPS. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS’ customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide. Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” was launched in February 2020; however, the Company does not anticipate installations moving forward. The Company is in the process of determining a divestment and winddown plan for Softell and IPS. On January 25, 2025, the Company’s Board of Directors approved the preparation of a divestment and winddown plan for the winddown of each of Softell, IPS, Bonum Health, Inc., and Bonum. Scienture, LLC (f/k/a Scienture, Inc.) (“Scienture”) is a New York based branded, specialty pharmaceutical research company which is engaged in the research and development of branded pharmaceutical products. The intellectual property application process was initiated in November 2019 and the product development activities commenced in January 2020. Scienture also plans to foray into commercialization of innovative and branded pharmaceutical products in the US market. Scienture’s assets in development are across therapeutics areas and indications and cater to different market segments. Scienture’s mission is to identify, develop and bring to market innovative technology-based products to address unmet medical needs. Its targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. Acquisitions Superlatus Merger On July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Superlatus Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”). 89 Table of Contents On July 31, 2023, the Company completed its acquisition of Superlatus in accordance with the terms and conditions of the Superlatus Merger Agreement (the “Superlatus Merger”), pursuant to which the Company acquired Superlatus by way of a merger of the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the Superlatus Merger. Under the terms of the Superlatus Merger Agreement, at the closing of the Superlatus Merger, shareholders of Superlatus received an aggregate of 136,441 shares of the Company’s common stock and 306,855 shares of the Company’s Series B Preferred Stock, par value $ 0.00001 per share (the “Series B Preferred Stock”). Each share of Series B Preferred Stock is convertible into 100 shares of the Company’s common stock. At Closing, the value of the Company’s common stock was $ 7.30 per share, resulting in a total value of $ 225,000,169 . Upon consummation of the Superlatus Merger, the Company continued to trade under its former ticker symbol “MEDS”. Not all of the closing conditions of the Superlatus Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the Amended and Restated Agreement and Plan of Merger (the “Superlatus Amendment”) on January 8, 2024. Under the terms of the Superlatus Amendment, the merger consideration to the shareholders of Superlatus was adjusted to an aggregate of 136,441 shares of the Company’s common stock and 15,759 shares of the Company’s Series B Preferred Stock, resulting in a total value of $ 12,500,089 . Additionally, the shareholders of Superlatus agreed to surrender back to the Company 291,096 shares of the Company’s Series B Preferred Stock. As described below, in March 2024, the Company divested of its interest in Superlatus. Scienture Merger On July 25, 2024, the Company entered into and closed an Agreement and Plan of Merger (the “Scienture Merger Agreement”) with MEDS Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub I”), MEDS Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), and Scienture. Pursuant to the Scienture Merger Agreement, (i) Merger Sub I merged with and into Scienture (the “First Merger”), with Scienture continuing as the surviving entity and a wholly owned subsidiary of the Company, and (ii) Scienture merged with and into Merger Sub II (the “Second Merger” and, together with the First Merger and all other related transactions, the “Scienture Merger”), with Merger Sub II continuing as the surviving entity. In connection with the transactions, the Company changed its name to “Scienture Holdings, Inc.” and Merger Sub II, as the surviving entity of the Second Merger, changed its name to “Scienture, LLC”. As consideration for the Scienture Merger, at the effective time of the First Merger (the “Effective Time”), the shares of Scienture common stock issued and outstanding immediately prior to the Effective Time were converted into the right to receive, in the aggregate, (i) 291,536 shares of the Company’s common stock and (ii) 6,826,753 shares of the Company’s Series X Non-Voting Convertible Preferred Stock (the “Series X Preferred Stock”), each share of which is convertible into one share of common stock. Scienture LLC is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture is developing a broad range of novel product candidates including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The intellectual property application process was initiated in November 2019 and the product development activities commenced in January 2020. Scienture’s assets in development are across therapeutics areas and indications and cater to different market segments. Scienture’s mission is to identify, develop and bring to market innovative technology-based products to address unmet medical needs. Its targeted portfolio consists of short term and long-term opportunities with efficient development, regulatory, and go to market strategies. 90 Table of Contents Dispositions MMS APA On February 16, 2024, the Company, together with Softell and Micro Merchant Systems, Inc. (“MMS”), entered into an asset purchase agreement (the “MMS APA”) under which MMS agreed to purchase for cash substantially all of the assets of Softell. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the MMS APA. Softell operated a web-based market platform designed to enable trading among healthcare buyers and sellers of pharmaceuticals, accessories and services. The purchase price paid at closing was $ 22,660,182 . Pursuant to the terms and conditions of the MMS APA, because MMS received $ 1,600,000 or greater in certain collections from third parties resulting from any products or services sold, or provided, by the business assets and operations acquired from Softell during the period ending on the four-month anniversary of the closing date, the Company was due an additional $ 7,500,000 payment from MMS. The Company received the $ 7,500,000 in May 2024. Superlatus SPA On March 5, 2024, the Company entered into a Stock Purchase Agreement (the “Superlatus SPA”) with Superlatus Foods Inc. (the “Buyer”). Pursuant to the Superlatus SPA, the Company sold all of the issued and outstanding stock of Superlatus to the Buyer. The $ 1.00 purchase price for the stock was delivered to the Company at the closing, which occurred simultaneously with the execution of the Superlatus SPA. As a result of the transaction, Superlatus ceased to be a subsidiary of the Company, and the rights and assets of Superlatus together with various liabilities and obligations that were specific to Superlatus became rights and obligations of the Buyer. See Note 3 for further detail on the dispositions. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements include the accounts of Scienture LLC, TRxADE Health, Inc., Softell, Integra Pharma Solutions, Inc., and Bonum Health. The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the SEC. All significant intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from its estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected. Significant estimates for the years ended December 31, 2024 and 2023 include the valuation of intangible assets, including goodwill, valuation of derivative liabilities and gain (losses) on dispositions. 91 Table of Contents Fair Value of Financial Instruments Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying amounts for cash, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate their fair value because of their short-term maturity. The Company’s notes payables approximate the fair value of such instruments as the notes bear interest rates that are consistent with current market rates. The Company’s derivative liability is a Level 3 liability measured at fair value on a recurring basis. See Note 10. Stock Split Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date . This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $ 1.00 . Recently Issued Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The new guidance requires enhanced disclosure of significant expenses that are regularly reported to the chief operating decision maker and the nature of segment expense information used to manage operations. The new guidance is effective for all public companies for annual reporting periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted ASU 2023-07 on January 1, 2024. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) : Improvements to Income Tax Disclosures . The new guidance requires disaggregated information about the effective tax rate reconciliation and additional information on taxes paid that meet a quantitative threshold. The new guidance is effective for public companies for annual reporting periods beginning after December 15, 2024, and for non-public companies for annual reporting periods beginning after December 15, 2025, with early adoption permitted for both. The Company will adopt the new standard in annual reporting period beginning after December 15, 2025, and is currently evaluating the impacts of the new guidance on its disclosures within the consolidated financial statements. 92 Table of Contents Concentration of Credit Risks and Major Customers Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits. During years ended December 31, 2024 and 2023, no sales to customers represented greater than 10 % of revenue. Accounts Receivable, net On January 1, 2023, the Company adopted ASU 2016-13 “ Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired, and each subsequent reporting period. The Company’s receivables are from customers and are typically collected within 90 days. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Other Receivables As of December 31, 2024 and 2023, other receivables are $ 4,138,770 and $ 1,224,702 . As of December 31, 2024, other receivables primarily consist of short-term advances to related parties including Wellgistics Health, Inc. (f/k/a Danam Health Inc.) and Tollo Health, Inc. Deferred Offering Costs The Company complies with the requirements of Accounting Standards Codification (“ASC”) 340-10-S99-1 with regards to offering costs. Prior to the completion of an offering, offering costs are capitalized. The deferred offering costs are charged to additional paid-in capital or as a discount to debt, as applicable, upon the completion of an offering or to expense if the offering is not completed. As of December 31, 2024 and 2023, the Company has $ 534,800 and $ 0 , respectively, capitalized deferred offering costs. See Note 11. Derivative Financial Instruments The Company evaluates its convertible notes to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Acquisitions The Company accounts for acquisitions and investments in businesses as business combinations if the target meets the definition of a business and (a) the target is a variable interest entity (“VIE”) and the Company is the target’s primary beneficiary, and therefore the Company must consolidate its financial statements, or (b) the Company acquires more than 50% of the voting interest of the target and it was not previously consolidated. The Company records business combinations using the acquisition method of accounting, which requires all the assets acquired and liabilities assumed to be recorded at fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired is recorded as goodwill. 93 Table of Contents The application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized from goodwill. The fair value assigned to tangible and intangible assets acquired and liabilities assumed are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Significant assumptions and estimates include, but are not limited to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital, and the cost savings expected to be derived from acquiring an asset, if applicable. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the Company’s financial statements may be exposed to potential impairment of the intangible assets and goodwill. If the Company’s investment involves the acquisition of an asset or group of assets that does not meet the definition of a business, the transaction is accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalizing transaction costs, and does not result in the recognition of goodwill. On July 25, 2024, the Company acquired intangible assets of $ 76,400,000 and recognized goodwill of $ 21,372,960 pursuant to the Scienture acquisition (see Note 3). The acquired goodwill represents the value in excess of the net assets and liabilities acquired at the acquisition date. Goodwill Goodwill is an asset representing the excess cost over the fair market value of net assets acquired in business combinations. In accordance with Intangibles - Goodwill and Other (Topic 350), goodwill is not amortized but is tested annually for impairment or on an interim basis when indicators of potential impairment exist. Goodwill is tested for impairment at the reporting unit level. The Company’s reporting units discrete financial information is available and management regularly reviews the operating results. For purposes of impairment testing, goodwill is allocated to the applicable reporting units based on the reporting structure. The Company has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors assessed for each of the applicable reporting units include, but are not limited to, changes in macroeconomic conditions, industry and market considerations, cost factors, discount rates, competitive environments and financial performance of the reporting units. If the qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, a quantitative test is required. The Company also has the option to proceed directly to the quantitative test. Under the quantitative impairment test, the estimated fair value of each reporting unit is compared to its carrying value, including goodwill. If the carrying value of the reporting unit including goodwill exceeds its fair value, an impairment charge equal to the excess would be recognized, up to a maximum amount of goodwill allocated to that reporting unit. Management can resume the qualitative assessment in any subsequent period for any reporting unit. As of December 31, 2024, management performed a qualitative impairment assessment of our reporting units, of which there were no indications that it was more likely than not that the fair value of our reporting units were less than their respective carrying values. As such, a quantitative goodwill test was not required, and no goodwill impairment was recognized during the year ended December 31, 2024. Intangible Assets In connection with the Scienture acquisition, the Company identified product technologies assets. The product technologies represent a broad range of novel product candidates including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. Each of the product technologies are in various phases of development and had not achieved regulatory approval as of the valuation date. 94 Table of Contents The product technologies are 505(b)(2) products and represent modifications and new delivery methods of already approved drugs (rather than novel drug compounds/formulations/treatments which require significant regulatory approvals and testing). These assets should be amortized over their expected remaining economic life. The product technology assets will remain unamortized, subject to potential impairment testing, until the assets are placed in service, which is when commercialization of the product commences. At that point, the assets will be amortized over their expected remaining life (likely a period of 15 - 20 years based on the patent lives). Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. The Company did not record an impairment charge for the years ended December 31, 2024 and 2023. Investments The Company accounts for investments that it does not control using the cost method, equity method or fair value method, as applicable. Investments in companies in which the Company owns less than a 20% equity interest and where it does not exercise significant influence over the operating and financial policies of the investee are accounted for using the cost method of accounting. The Company periodically reviews the carrying value of these investments to determine if there has been an other-than-temporary decline in fair value below carrying value. A variety of factors are considered when determining if a decline in fair value below carrying value is other-than-temporary, including, among others, the financial condition and business prospects of the investee, as well as the Company’s investment intent. Cost method investments are carried at cost, which approximates or is less than fair value. Dividends received by the Company are recognized in equity (losses) earnings of affiliates, net of tax on the consolidated statements of operations. On February 29, 2024, Softell entered into a Subscription Agreement (the “Subscription Agreement”) with Lafayette Energy Corp., a Delaware corporation (“Lafayette”). Pursuant to the Subscription Agreement, Softell will, in two equal tranches, invest a total of up to $ 5,000,000 in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s Series A Convertible Preferred Stock, with the second tranche becoming payable only upon Softell’s receipt of notice that Lafayette has successfully drilled its first oil and gas well and produced at least one hundred (100) barrels of oil. As of December 31, 2024, the Company evaluated the financial condition and business prospects of Lafayette, and determined there was an other-than-temporary decline in fair value below carrying value. As such, the Company recognized an impairment of $ 2,500,000 . Stock-Based Compensation The Company accounts for stock-based compensation to employees in accordance with ASC 718, “Compensation-Stock Compensation”. ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant date fair value of the award and to recognize it as compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period. Stock option forfeitures are recognized at the date of employee termination. Effective January 1, 2019, the Company adopted ASU 2018-07 for the accounting of share-based payments granted to non-employees for goods and services. 95 Table of Contents Leases The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term. Research & Development Expenses Research and development costs are expensed in the period incurred in accordance with ASC 730, Research and Development. These expenses consist of independent contractor costs, costs for outsourced analytical research and development activities, batch manufacturing cost and, advisory costs as a part of research, market research costs and other regulatory consulting costs. Income (loss) Per Common Share Basic net income per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted net income per common share is computed similar to basic net income per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The dilutive effect of the Company’s options and warrants is computed using the treasury stock method. As of December 31, 2024, we had 238,594 warrants to purchase shares of common stock, 15,759 shares of Series B preferred stock and 23,930 options to purchase shares of common stock, all outstanding The following table sets forth the computation of basic and diluted loss per share: SCHEDULE OF BASIC AND DILUTIVE LOSS PER SHARE 2024 2023 Year Ended December 31, 2024 2023 Numerator: Net loss from continuing operations $ ( 18,244,480 ) $ ( 8,482,864 ) Net income (loss) on discontinued operations 27,310,278 ( 9,360,710 ) Net income (loss) $ 9,065,798 $ ( 17,843,574 ) Denominator: Denominator for EPS – weighted average shares Basic 3,375,325 764,058 Diluted 3,653,609 2,381,443 Net loss per common share from continuing operations Basic $ ( 5.41 ) $ ( 11.10 ) Diluted $ ( 5.41 ) $ ( 11.10 ) Net income (loss) per common share from discontinued operations Basic $ 8.09 $ ( 12.25 ) Diluted $ 7.47 $ ( 3.93 ) Net income (loss) Basic $ 2.69 $ ( 23.35 ) Diluted $ 2.48 $ ( 23.35 ) 96 Table of Contents Income taxes The Company’s benefit / (provision) for income taxes was $ 534,396 and $ 0 for the years ended December 31, 2024 and 2023, respectively. The income tax provisions for these periods are based upon estimates of annual income (loss), annual permanent differences and statutory tax rates in the various jurisdictions in which the Company operates. For all periods presented, the Company utilized net operating loss carryforwards to offset the impact of any taxable income. The Company’s tax rate differs from the applicable statutory rates due primarily to the establishment of a valuation allowance, utilization of deferred and the effect of permanent differences and adjustments. NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of December 31, 2024, the Company had an accumulated deficit of $ 39,038,973 and $ 308,096 in cash. We will need to raise additional capital or secure debt funding to support on-going operations, and to fund the assets and operations of any businesses or assets we acquire. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. NOTE 3 – ACQUISITIONS AND DISPOSITIONS Acquisitions Scienture, Inc. The Company evaluated the Scienture Merger Agreement pursuant to ASC 805 and ASU 2017-01, Topic 805, Business Combinations . The Company first determined that Scienture met the definition of a business as it includes inputs and a substantive process that together significantly contribute to the ability to create outputs. Scienture’s results of operations are included in the Company’s consolidated financial statements from the date of acquisition. The acquisition method of accounting requires, among other things, that the assets acquired and liabilities assumed in a business combination be measured at their estimated respective fair values as of the closing date of the acquisition. Goodwill recognized in connection with this transaction represents primarily the potential economic benefits that the Company believes may arise from the acquisition. The purchase price allocation is preliminary and could be significantly revised as a result of additional information obtained regarding assets acquired and liabilities assumed and revisions of estimates of fair values of tangible assets and related deferred tax assets and liabilities. The Company will finalize its valuation and the allocation of the purchase price, along with required retrospective adjustments, if any, within a year following the acquisition date. On July 25, 2024, the Company issued 291,536 shares of common stock and 6,826,753 shares of Series X Preferred Stock pursuant to the Scienture Merger Agreement. The aggregate fair value of the purchase price consideration was $ 78,646,184 . The fair value was determined by the underlying stock price of the common stock on the date of the Scienture Merger, which was $ 11.63 per share, which was utilized for both the issuance of common and preferred stock after evaluating the terms of the Series X Preferred Stock. The Company also applied a discount for lack of marketability of 5% due to certain lock-up terms on the shares issued. 97 Table of Contents The following summarizes the purchase price consideration and the preliminary purchase price allocation as of the acquisition date: SCHEDULE OF PURCHASE PRICE ALLOCATION July 25, 2024 Purchase consideration: Common stock $ 3,221,245 Series X preferred stock 75,424,939 Total purchase consideration $ 78,646,184 Purchase price allocation: Cash $ 132,976 Operating lease right-of-use assets 61,578 Goodwill 21,372,960 Intangible assets - product technologies 76,400,000 Prepaid expenses Inventory Accounts payable ( 987,097 ) Accrued liabilities ( 1,198,134 ) Loan payable, related party ( 265,000 ) Lease liability ( 61,886 ) Development agreement liability ( 1,285,000 ) Long-term convertible notes ( 2,000,000 ) Deferred tax liability ( 13,524,213 ) Accounts payable and other current liabilities Purchase price payable Notes payable Net assets acquired $ 78,646,184 Goodwill is primarily attributable to the go-to-market synergies that are expected to arise as a result of the acquisition and other intangible assets that do not qualify for separate recognition. The goodwill is not deductible for tax purposes. The results of Scienture have been included in the consolidated financial statements since the date of acquisition. Scienture’s revenue and net loss included in the consolidated financial statements since the acquisition date through December 31, 2024 were $ 0 and a loss of $ 3,509,597 , respectively. Unaudited Pro Forma Financial Information The following unaudited pro forma financial information presents the Company’s financial results as if the Scienture Merger had occurred as of January 1, 2023. The unaudited pro forma financial information is not necessarily indicative of what the financial results actually would have been had the acquisitions been completed on this date. In addition, the unaudited pro forma financial information is not indicative of, nor does it purport to project, the Company’s future financial results. The pro forma information does not give effect to any estimated and potential cost savings or other operating efficiencies that could result from the acquisition: SCHEDULE OF PRO FORMA FINANCIAL INFORMATION 2024 2023 Year Ended December 31, 2024 2023 Revenue $ 136,643 $ 1,863,830 Net loss from continuing operations $ ( 23,525,452 ) $ ( 9,698,339 ) Net loss from continuing operations per share $ ( 6.97 ) $ ( 12.69 ) Superlatus, Inc. On July 31, 2023, the Company entered into the Superlatus Merger Agreement (see Note 1) with Superlatus whereby the Company acquired 100 % of the stock of Superlatus in the Superlatus Merger. Superlatus includes a wholly-owned subsidiary, Sapientia. Consideration for the Superlatus Merger consisted of (i) 136,441 shares of the Company’s common stock at a fair value of $ 7.30 per share and (ii) 306,855 shares of the Company’s Series B Preferred Stock, each share of which is convertible into 100 shares of common stock. The total fair value of the common stock and Series B Preferred Stock on the closing date was $ 225,000,169 (the “Purchase Price”). On January 8, 2024, the Company entered into the Superlatus Amendment. Under the terms of the Superlatus Amendment, the merger consideration to the shareholders of Superlatus was adjusted to an aggregate of 136,441 shares of the Company’s common stock and 15,759 shares of the Company’s Series B Preferred Stock. The total fair value of the common stock and Series B Preferred Stock on the closing date was adjusted to $ 12,500,089 (the “Amended Purchase Price”). Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s Series B Preferred Stock received before the Superlatus Amendment. 98 Table of Contents The acquisition of Superlatus was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, the Company had estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. An independent valuation expert assisted the Company in determining these fair values. The Amended Purchase Price allocation as of the acquisition date is presented as follows: SCHEDULE OF PURCHASE PRICE ALLOCATION July 31, 2023 Purchase consideration: Common Stock, at fair value $ 996,019 Series B Preferred Stock, at fair value 11,504,070 Total purchase consideration $ 12,500,089 Purchase price allocation: Cash $ 5,546 Prepaid expenses 3,705 Inventory 122,792 Intangible assets, net 9,777,479 Goodwill 5,129,115 Assets acquired 15,038,637 Accounts payable and other current liabilities ( 283,548 ) Purchase price payable ( 350,000 ) Notes payable ( 1,905,000 ) Liabilities assumed ( 2,538,548 ) Net assets acquired $ 12,500,089 The Urgent Company, Inc. On September 27, 2023, the Company entered into an Asset Purchase Agreement (the “TUC APA”) with The Urgent Company, Inc. (“TUC”) and its wholly owned subsidiaries, pursuant to which, the Company was assigned certain inventory and property and equipment and assumed certain operating leases for consideration of $ 4,400,000 in promissory notes (see Note 11). Subsequent to December 31, 2023, we divested our interest in TUC. The transaction was accounted for as an asset acquisition pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, the Company allocated the cost of the asset acquisition to the assets acquired and liabilities assumed as of the acquisition date based on their respective relative fair value as of the date of the transaction. The following summarizes the provisional relative fair values of the assets acquired as of the acquisition date based on the allocation of the cost of the asset acquisition: SCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED September 27, 2023 Purchase consideration: Promissory note $ 4,400,000 Total purchase consideration $ 4,400,000 Allocation of cost of assets acquired: Inventory $ 4,168,830 Property and equipment 231,170 Assets acquired 4,400,000 Net assets acquired $ 4,400,000 99 Table of Contents Dispositions and Divestitures Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC On August 22, 2023, the Company and Wood Sage, LLC (“Wood Sage”) entered into (i) a Membership Interest Purchase Agreement (the “APS MIPA”), pursuant to which the Company sold its 100 % membership interest in Alliance Pharma Solutions, LLC (“APS”) for consideration of a $ 125,000 promissory note (the “APS Sale Price”) and (ii) a Membership Interest Purchase Agreement (the “CSP MIPA”), pursuant to which the Company sold 100 % of the membership interest in Community Specialty Pharmacy, LLC (“CSP”) in exchange for a $ 100,000 promissory note (the “CSP Sale Price”). As a result, the results of APS and CSP were classified as discontinued operations in our consolidated statements of operations and excluded from both continuing operations and segment results for the year ended December 31, 2023. As part of recognizing the business as held for sale in accordance with U.S. GAAP, the Company was required to measure APS and CSP at the lower of its carrying amount or fair value less cost to sell. As a result of this analysis, during the year ended December 31, 2023, the Company recognized a non-cash, pre-tax loss on disposal of $ 3,300,225 . The loss is included in “Net loss from discontinued operations” in the consolidated statements of operations. The loss was determined by comparing the fair value of the consideration received for the sale of a 100% interest in APS and CSP with the net assets of APS and CSP, respectively, immediately prior to the transaction. As a result of the transactions, the following assets and liabilities of APS and CSP were transferred to Wood Sage as of August 22, 2023: SCHEDULE OF ASSETS AND LIABILITIES Alliance Pharma Solutions, LLC Community Specialty Pharmacy, LLC Cash $ 1,050 $ 61,988 Accounts receivable, net - 101,901 Inventory - 123,230 Prepaid assets - 525 Intangible assets and capitalized software, net 739,337 - Accounts payable ( 23,982 ) ( 231,876 ) Accrued liabilities - ( 10,182 ) Net assets sold $ 716,405 $ 45,586 MMS APA On February 16, 2024, the Company, together with Softell and MMS, entered into the MMS APA under which MMS agreed to purchase for cash substantially all of the assets of Softell. On February 16, 2024, the parties consummated the closing of the transactions contemplated by the MMS APA. The purchase price paid at closing was $ 22,660,182 . Subject to the terms and conditions of the MMS APA, because MMS received $ 1,600,000 or greater in certain collections from third parties resulting from any products or services sold, or provided, by the business assets and operations acquired from Softell during the period ending on the four-month anniversary of the closing date, the Company was due an additional $ 7,500,000 payment from MMS. The Company received the payment in May 2024. 100 Table of Contents The MMS APA was accounted for a business disposition in accordance with ASC 810-40-40-3A. As of February 16, 2024, the Company no longer consolidated the assets, liabilities, revenues and expenses of Softell. The components of the disposition are as follows: SCHEDULE OF BUSINESS ACQUISITIONS ASSETS AND LIABILITIES Cash received from MMS $ 22,660,182 Other receivable from MMS 7,500,000 Fair value of consideration received - Total fair value of consideration received $ 30,160,182 Carrying amount of assets and liabilities Cash $ 76,821 Accounts receivable, net 719,876 Prepaid expenses 55,397 Property, plant and equipment, net 45,655 Intangible assets, net Operating lease right-of-use assets 12,277 Purchase price payable Accounts payable ( 347,000 ) Accrued liabilities ( 5,269 ) Other current liabilities ( 26,244 ) Lease liability, current ( 1,556 ) Notes payable, current portion ( 45,000 ) Lease liability, net of current portion ( 10,720 ) Notes payable Total carrying amount of assets and liabilities 474,236 Gain on disposition of business $ 29,685,946 The gain on disposition of business of $ 29,685,946 was included in income from discontinued operations, net of tax in the consolidated statements of operations. Superlatus SPA On March 5, 2024, the Company entered into the Superlatus SPA with the Buyer. Pursuant to the Superlatus SPA, the Company sold all of the issued and outstanding stock of Superlatus to the Buyer. The $ 1.00 purchase price for the stock was delivered to the Company at the closing, which occurred simultaneously with the execution of the Superlatus SPA. As a result of the transaction, Superlatus ceased to be a subsidiary of the Company, and the rights and assets of Superlatus together with various liabilities and obligations that were specific to Superlatus became rights and obligations of the Buyer. The transaction was accounted for a business disposition in accordance with ASC 810-40-40-3A. As of March 5, 2024, the Company no longer consolidated the assets, liabilities, revenues and expenses of Superlatus. The components of the disposition are as follows: SCHEDULE OF BUSINESS ACQUISITIONS ASSETS AND LIABILITIES Fair value of consideration received $ 1 Total fair value of consideration received $ 1 Carrying amount of assets and liabilities Cash $ 151,546 Property, plant and equipment, net 223,080 Intangible assets, net 8,962,688 Operating lease right-of-use assets 325,995 Purchase price payable ( 350,000 ) Accounts payable ( 224,137 ) Accrued liabilities ( 173,436 ) Notes payable, current portion ( 6,480,000 ) Lease liability - current ( 105,567 ) Lease liability - net of current portion ( 221,428 ) Notes payable ( 25,000 ) Total carrying amount of assets and liabilities 2,083,743 Loss on disposition of business $ ( 2,083,742 ) The loss of disposition of business of $ 2,083,742 was included in income from discontinued operations, net of tax in the consolidated statements of operations. 101 Table of Contents Discontinued Operations In accordance with the provisions of ASC 205-20, the Company has excluded the results of discontinued operations from its results of continuing operations in the accompanying consolidated statements of operations for the years ended December 31, 2024 and 2023. As of December 31, 2024, we had $ 8,145 of the current assets from discontinued operations, comprised of accounts receivable and $ 5,346 of current liabilities from discontinued operations, comprised of accounts payable of $ 5,211 and accrued liabilities of $ 135 . The results of the discontinued operations for the years ended December 31, 2024 and 2023 consist of the following: SCHEDULE OF DISCONTINUED OPERATIONS 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 TRX Bonum Superlatus SOSRx CSP APS Total Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended Year Ended December 31, December 31, December 31, December 31, December 31, December 31, December 31, 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Revenues $ 970,808 $ 6,402,159 $ - $ 19,204 $ - $ 487,021 $ - $ - $ - $ 851,755 $ - $ - $ 970,808 $ 7,760,139 Cost of sales - - - - - 4,359,156 - - - 705,206 - - - 5,064,362 Gross profit (loss) 970,808 6,402,159 - 19,204 - ( 3,872,135 ) - - - 146,549 - - 970,808 2,695,777 Operating expenses: Wage and salary expense 713,021 1,982,268 578 89,363 - - - - - 456,297 - - 713,599 2,527,928 Professional fees 62,160 218,407 - - - 373,025 - - - 20,246 - 3,125 62,160 614,803 Technology expense 86,660 1,201,405 2,244 75,745 - 26,972 - - - 72,464 - 28,383 88,904 1,404,969 General and administrative 37,377 489,817 678 6,765 - 952,415 - - - 32,830 - 3,762 38,055 1,485,589 Total operating expenses 899,218 3,891,897 3,500 171,873 - 1,352,412 - - - 581,837 - 35,270 902,718 6,033,289 Operating income (loss) 71,590 2,510,262 ( 3,500 ) ( 152,670 ) - ( 5,224,547 ) - - - ( 435,288 ) - ( 35,270 ) 68,090 ( 3,337,513 ) Non-operating income (expense): Goodwill impairment - - - - - ( 5,129,116 ) - - - - - - - ( 5,129,116 ) Gain (loss) on dispositions 29,685,946 ( 207,192 ) - - ( 2,083,742 ) - - - - 25,008 - ( 671,317 ) 27,602,204 ( 853,501 ) Other expense - - - - - ( 7,562 ) - - - - - - - ( 7,562 ) Other income - 22,105 - - - - - - - - - - - 22,105 Interest expense - - - - - ( 55,123 ) - - - - - - - ( 55,123 ) Total non-operating income (expense) 29,685,946 ( 185,087 ) - - ( 2,083,742 ) ( 5,191,801 ) - - - 25,008 - ( 671,317 ) 27,602,204 ( 6,023,197 ) Provision for income taxes ( 360,016 ) - - - - - - - - - - - ( 360,016 ) Net income (loss) on discontinued operations $ 29,397,520 $ 2,325,175 $ ( 3,500 ) $ ( 152,670 ) $ ( 2,083,742 ) $ ( 10,416,348 ) $ - $ - $ - $ ( 410,280 ) $ - $ ( 706,587 ) $ 27,310,278 $ ( 9,360,710 ) In the second quarter of 2024, the Company determined to dissolve Bonum Health, Inc. and Bonum Health, LLC, and have presented the results of operations in net income (loss) from discontinued operations. 102 Table of Contents NOTE 4- RELATED PARTY TRANSACTIONS Wellgistics Health and Tollo Health On November 21, 2023, but effective September 14, 2023, the Company issued a promissory note (the “Wellgistics Note”) to Wellgistics Health, Inc. (f/k/a Danam Health Inc.) (“Wellgistics”) in the amount of $ 300,000 . Wellgistics prepaid $ 250,000 prior to the execution date. The Wellgistics Note did not accrue interest. As of December 31, 2023, the balance of the Wellgistics Note was $ 50,000 . The Wellgistics Note was fully paid off in February 2024. As of December 31, 2024, other receivables include a $ 3,923,770 receivable from Wellgistics and $ 215,000 receivable from Tollo Health. The advances are unsecured, non-interest bearing and due on demand. See Note 7 for detail on the note receivable from Wood Sage. Both Wellgistics Health and Tollo Health have common ownership and management with the Company. Lafyette On February 29, 2024, the Company’s wholly owned subsidiary, Softell, entered into the Subscription Agreement with Lafayette. Pursuant to the Subscription Agreement, Softell will, in two equal tranches, invest a total of up to $ 5,000,000 in Lafayette in exchange for up to 2,000,000 shares of Lafayette’s newly created Series A Convertible Preferred Stock, with the second tranche becoming payable only upon Softell’s receipt of notice that Lafayette has successfully drilled its first oil and gas well and produced at least one hundred (100) barrels of oil. As of December 31, 2024, the Company determined Lafayette’s investment to be impaired and recognized an impairment of $ 2,500,000 . Scienture In July 2024, the executives of Scienture issued a short-term loan to Scienture for an aggregate amount of $ 265,000 . The loans are unsecured, non-interest bearing and due on demand. The loans were still outstanding as of December 31, 2024. In November 2024, the executives of Scienture issued a short-term loan to Scienture for an amount of $ 150,000 . The loans are unsecured, non-interest bearing and due on demand. The loans were outstanding as of December 31, 2024. NOTE 5 – REVENUE RECOGNITION The Company derives revenue from one primary source—product revenue. Product revenue consists of shipments of: ● Resale of pharmaceutical products to pharmacies; and ● Revenues for our products are recognized and invoiced when the product is shipped to the customer. Revenues for one-time services are recognized at the point in time when services are rendered. Payment terms for products and services are generally 0 to 60 days and the Company has no contract assets or liabilities. Revenues for the years ended December 31, 2024 and 2023 were $ 136,643 and $ 1,363,830 , respectively. 103 Table of Contents NOTE 6 – INVENTORY Inventory value is determined using the weighted average cost method and is stated at the lower of cost or net realizable value. As of December 31, 2024 and 2023, inventory was comprised of the following: SCHEDULE OF INVENTORY 2024 2023 December 31, 2024 2023 Finished goods $ - $ 968 Inventory $ - $ 968 Prepaid expenses and other current assets included $ 750,000 in deposits for future inventory was written off during the year ended December 31, 2024. NOTE 7 – NOTES RECEIVABLE – RELATED PARTY On August 22, 2023, the Company received a Promissory Note (the “Wood Sage Note”) in the amount of $ 1,300,000 from Wood Sage. The Wood Sage Note bears no interest and is currently due and payable. As of both December 31, 2024 and 2023, the outstanding balance of the Wood Sage Note was $ 1,300,000 . NOTE 8 – GOODWILL AND INTANGIBLE ASSETS In connection with the Scienture Merger on July 25, 2024, the Company recorded goodwill of $ 21,372,960 and intangible assets of $ 76,400,000 . The purchase price allocation of intangible assets was evaluated under ASC 805. The identified intangible assets were determined to be product technologies, and were valued accordingly by each product candidate: SCHEDULE OF INTANGIBLE ASSETS WERE DETERMINED TO BE PRODUCT TECHNOLOGIES Product Candidate Fair Value SCN-102 (a) $ 23,600,000 SCN-104 (b) 25,000,000 SCN-106 (c) 15,000,000 SCN-107 (d) 12,800,000 Intangible Assets $ 76,400,000 (a) Management expects SCN-102 to achieve regulatory approval in late 2024, with product commercialization projected to begin in 2025. (b) Management expects SCN-104 to achieve regulatory approval in late 2025 or early 2026, with product commercialization projected to begin in 2026. (c) Management expects SCN-106 to achieve regulatory approval in 2027 or 2028, with product commercialization projected to begin in 2028. (d) Management expects SCN-107 to achieve regulatory approval in 2028 or 2029, with product commercialization projected to begin in 2029. The fair value of the product technologies was determined by the Income Approach: Multi-Period Excess Earnings Methods (“MPEEM”). The MPEEM measures economic benefits by calculating the cash flows attributable to an asset after deducting appropriate returns for contributory assets used by the business in generating the asset’s revenue and earnings. The MPEEM utilized revenue and cash flow projections through 2030 based on each product candidate’s phase of development. Key assumptions include a 2% long-term revenue growth rate and 3% contributory asset charge rate. The Company discounted the expected future cash flows at a 53.0% rate of return, equal to the weighted-average cost of capital (“WACC”) plus 10%, to reflect the risk of the cash flows related to the product technologies. The Company then summed the present values of the estimated future cash flows and included an amortization tax benefit to the value indication of each of the product technologies. As of December 31, 2024, the Company has not begun amortizing any of the product technology intangible assets. NOTE 9 – CONTINGENT FUNDING LIABILITIES On December 13, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “December Receivables Agreement”). Pursuant to the December Receivables Agreement, the third party agreed to fund the Company $ 150,000 to purchase $ 214,500 of future receivables. The Company also paid $ 7,500 as a one-time origination fee in connection with the December Receivables Agreement. This agreement was fully paid off in February 2024. 104 Table of Contents On November 22, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “November Receivables Agreement”). Pursuant to the November Receivables Agreement, the third party agreed to fund the Company $ 275,000 to purchase $ 393,250 of future receivables. The Company also paid $ 13,750 as a one-time origination fee in connection with the November Receivables Agreement. This agreement was fully paid off in February 2024. On October 25, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “October Receivables Agreement”). Pursuant to the October Receivables Agreement, the third party agreed to fund the Company $ 1,200,000 to purchase $ 1,728,000 of future receivables. The Company also paid $ 60,000 as a one-time origination fee in connection with the October Receivables Agreement. This agreement was fully paid off in February 2024. The Company’s relationship with the funding source meets the criteria in ASC 470-10-25 – Sales of Future Revenues or Various Other Measures of Income (“ASC 470”), which relates to cash received from a funding source in exchange for a specified percentage or amount of revenue or other measure of income of a particular product line, business segment, trademark, patent or contractual right for a defined period. Under this guidance, the Company recognized the fair value of its contingent obligation to the funding source, as of the acquisition date, as a current liability in its consolidated balance sheet. Under ASC 470, amounts recorded as debt are to be amortized under the interest method. The Company made an accounting policy election to utilize the prospective method when there is a change in the estimated future cash flows, whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining period. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield. As of December 31, 2024, and 2023, the total contingent funding liability was $ 0 and $ 1,246,346 respectively, and the effective interest rate was approximately 0 % and 31 %, respectively. This rate represents the discount rate that equates the estimated future cash flows with the fair value of the debt and is used to compute the amount of interest to be recognized each period. Any future payments made to the funding source will decrease the contingent funding liability balance accordingly. NOTE 10 – CONVERTIBLE DEBT AND NOTES PAYABLE Convertible Debenture – Arena On November 22, 2024, the Company entered into a Securities Purchase Agreement with the Arena Finance Markets, LP (“Arena Finance”), Arena Special Opportunities Partners III, LP (“ASOP” and, together with Arena Finance, the “Arena Investors”). Under the Securities Purchase Agreement, the Company will issue 10 % original issue discount secured convertible debentures (“Debentures”) in a principal amount of up to $ 12,222,222 , divided into up to three separate tranches that are each subject to certain closing conditions. The conversion price per share of each Debenture is equal to 92.5 % of the lowest daily VWAP (as defined in the Debentures) of the Company’s shares of common stock during the five trading day period ending on the trading day immediately prior to delivery or deemed delivery of the applicable conversion notice, subject to adjustments related to the trading price of the Company’s common stock. The closing of the first tranche was consummated on November 25, 2024 (the “First Closing”) and the Company issued to the Arena Investors Debentures in an aggregate principal amount of $ 3,333,333 (the “First Closing Debentures”). The First Closing Debentures were sold to the Arena Investors for a purchase price of $ 3,000,000 , representing an original issue discount of ten percent ( 10 %). The convertible debenture will be matured eighteen months from the date first closing. 105 Table of Contents The First Closing Debentures contain customary events of default. If an event of default occurs, until it is cured, the holder may increase the interest rate applicable to the First Closing Debentures to two percent ( 2 %) per annum and accelerate the full indebtedness under the First Closing Debentures, in an amount equal to 125 % of the outstanding principal amount and accrued and unpaid interest. Subject to limited exceptions set forth in the First Closing Debentures, the First Closing Debentures prohibit the Company and, as applicable, its subsidiaries from incurring any new indebtedness that is not subordinated to the Arena Investors and, as applicable, any subsidiary’s obligations in respect of the First Closing Debentures until the First Closing Debentures are paid in full. As consideration for the Arena Investors’ consummation of the First Closing, concurrently with the First Closing, the Company issued to each Arena Investor participating in the First Closing its pro rata portion of the 55,000 shares of common stock (the “SPA Commitment Fee Shares”) issued to the Arena Investors as a commitment fee upon the execution of the Securities Purchase Agreement. Furthermore, as consideration for the Arena Investors’ consummation of subsequent closings, the Company shall issue to the Arena Investors participating in such closing a certain number of Company common stock as agreed upon among the Company and the Arena Investors participating. The fair value of the shares of common stock issued was $ 420,200 , which was included as a debt discount as noted below. The Company agreed, pursuant to a Security Agreement, dated November 25, 2024 (the “Security Agreement”), to grant the Arena Investors a security interest in all of its assets to secure the prompt payment, performance, and discharge in full of all of the Company’s obligations under the Debentures. In addition, the Company’s wholly-owned subsidiary, Scienture, LLC, entered into a Guarantee Agreement, dated November 25, 2024 (the “Guarantee”), with the Arena Investors, pursuant to which it agreed to guarantee the prompt payment, Interest shall accrue on the outstanding principal amount of this Debenture at a rate equal to 10.00 % per annum paid in kind (the “PIK Interest”) unless there is an Event of Default, in which case Default Interest shall accrue and be paid instead of PIK Interest. The PIK Interest shall be added to the outstanding principal amount of this Debenture on a monthly basis as additional principal obligations hereunder and shall automatically and thereafter constitute a part of the outstanding principal amount for all purposes hereof (including the accrual of interest thereon at the rates applicable to the principal amount generally). The Company will not issue additional debentures to represent the PIK Interest. Interest shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, and shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal, together with all accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder, has been made. During the year ended December 31, 2024, the Company accrued $ 33,333 in interest expense pertaining to the Arena debentures. As a result of the debentures, the Company recognized an aggregate debt discount of $ 3,333,333 . Through December 31, 2024, $ 869,692 of the debt discount was amortized to interest expense. At December 31, 2024, the outstanding balance of the debentures, including the outstanding principal of $ 3,333,333 less the unamortized discount of $ 2,721,058 , was $ 612,275 . The following is a summary of the Arena Debentures: SCHEDULE OF THE ARENA DEBENTURES Arena Note Convertible debenture - Arena Principal $ 3,333,333 Original issuance discount ( 333,333 ) Other issuance costs ( 360,000 ) Fair value of shares issued ( 420,200 ) Derivative liability recognized as debt discount ( 2,477,217 ) Excess debt discount amortization at issuance date 257,417 Amortization of debt discount 612,275 Arena note, net of unamortized debt discount, at December 31, 2024 $ 612,275 106 Table of Contents Derivative Liability The Company evaluated the terms of the conversion features of the debentures as noted above in accordance with ASC Topic No. 815 - 40, Derivatives and Hedging - Contracts in Entity’s Own Stock, and determined they are not indexed to the Company’s common stock and that the conversion feature, which is akin to a redemption feature, meet the definition of a liability. The notes contain an indeterminate number of shares to settle with conversion options outside of the Company’s control. Therefore, the Company bifurcated the conversion feature and accounted for it as a separate derivative liability. Upon issuance of the convertible debenture, the Company recognized a derivative liability at a fair value of $ 2,477,217 , which is recorded as a debt discount and will be amortized over the life of the debentures. The Company measured the derivative liability at fair value based on significant inputs not observable in the market, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The valuation of the derivative liability uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the contingent consideration liability related to updated assumptions and estimates are recognized within the statements of operations. The Company valued the derivative liability using a Black-Scholes method using following assumptions: SCHEDULE OF DERIVATIVE LIABILITY TABLE TEXT BLOCK Initial Valuation Reporting Date November 25, December 31, 2024 2024 Risk-free interest rate 4.290 % 4.290 % Expected term (in years) 1.50 1.40 Expected volatility 170.56 % 171.46 % Expected dividend yield 0.00 % 0.00 % The following is a summary of the derivative liability: SCHEDULE OF THE DERIVATIVE LIABILITY LIABILITY Derivative Liability Outstanding as of December 31, 2023 $ - Issuance of embedded derivative liability 2,477,217 Change in fair value ( 180,383 ) Outstanding as of December 31, 2024 $ 2,296,834 Scienture Convertible Debt In September 2023, Scienture entered into a Loan and Security Agreement (the “NVK Loan Agreement”) with NVK Finance, LLC, a Nebraska Limited Liability Company (“NVK”) for $ 2,000,000 . The debt accrues interest at a per annum rate equal to the Prime Rate (as defined in the NVK Loan Agreement) plus 7 percent and the prime rates are adjusted quarterly. As of December 31, 2024, the interest rate was 15.50 %. The debt is collateralized by all of Scienture’s receivables, cash and cash equivalents and its right, title and interest in, to and under its Intellectual Property (as defined in the NVK Loan Agreement) and all proceeds thereof. The principal is entirely repayable on the maturity date in September 2025 and interest shall be paid monthly following a Qualified Financing (as defined in the NVK Loan Agreement). The NVK debt is convertible into common stock of Scienture at a fully-diluted Scienture valuation of $ 60,000,000 . The balance of the NVK debt upon the Scienture Merger and at December 31, 2024 was $ 2,000,000 . Interest expense on the NVK debt was $ 231,639 for the year ended December 31, 2024. 107 Table of Contents August 2024 Note In August 2024, the Company issued a convertible note of $ 360,000 , for which the Company received $ 314,000 in net proceeds. On the six-month anniversary of the issuance, the Company will be required to make a payment of $ 360,000 to the noteholder and each month thereafter the Company will be required to make a payment of $ 7,200 to the noteholder towards repayment of the note (each, an “Amortization Payment”). The note bears interest at 12 % per annum and shall be deemed earned in full and guaranteed as of the note issuance date. If the Company fails to pay any Amortization Payment, the noteholder will have the right to convert the outstanding principal and accrued interest at a conversion price equal to the Conversion Price (as defined below and subject to a floor price of $ 1.50 ). The Conversion Price is the lesser of i) $ 8.36 or (ii) 85 % of the lowest volume-weighted average prices of the preceding five trading days . The note matures on August 20, 2025 . During the year ended December 31, 2024, the Company incurred $ 43,200 in interest expense pertaining to the note. As of the issuance date of these financial statements, the note is still outstanding and the parties are working on an extension. In connection with the note, the Company issued 76,923 warrants to purchase common stock. The warrants have an exercise price of $ 9.36 per share, are immediately exercisable and have a term of 5 years. The fair value of the warrant was $ 71,332 , which was recognized as a debt discount and will be amortized to interest expense over the life of the note. Total debt discount recognized in connection with the note was $ 117,332 , of which $ 42,755 was amortized through December 31, 2024. The note payable, net of unamortized discount of $ 74,577 , was $ 285,423 as of December 31, 2024. Debt Summary The following is a summary of the Company’s debt as of December 31, 2024: SCHEDULE OF THE COMPANY’S DEBT Principal outstanding Unamortized debt discount Debt, net of unamortized debt discount As of December 31, 2024 Principal outstanding Unamortized debt discount Debt, net of unamortized debt discount Convertible debenture - Arena $ 3,333,333 $ ( 2,721,058 ) $ 612,275 August 2024 note 360,000 ( 74,577 ) 285,423 Scienture convertible debt 2,000,000 - 2,000,000 Total debt 5,693,333 ( 2,795,635 ) 2,897,698 Current maturity of debt 2,360,000 ( 74,577 ) 2,285,423 Total long-term debt $ 3,333,333 $ ( 2,721,058 ) $ 612,275 Superlatus Notes On November 17, 2023, the Company issued a promissory note to Moku Foods, Inc. (the “Moku Foods November 2023 Note”) in the amount of $ 50,000 . The promissory note accrues interest at 11.5 % per annum, compounded monthly and is payable upon demand at any time after November 30, 2023. As of December 31, 2023, the balance of the Moku Foods November 2023 Note was $ 50,000 . The Company has accrued interest of $ 945 as of December 31, 2023. On March 5, 2024, the Company entered into the Superlatus SPA, whereby the Company sold its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On October 16, 2023, the Company issued a promissory note to Moku Foods, Inc. (the “Moku Foods October 2023 Note”) in the amount of $ 150,000 . The promissory note accrues interest at 11.5 % per annum, compounded monthly and is payable upon demand at any time after October 31, 2023. As of December 31, 2023, the balance of the Moku Foods October 2023 Note was $ 150,000 . The Company has accrued interest of $ 4,300 as of December 31, 2023. On March 5, 2024, the Company entered into the Superlatus SPA, whereby the Company sold its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. 108 Table of Contents On September 27, 2023, the Company issued a promissory note to Perfect Day, Inc. (the “Perfect Day Note”) in the amount of $ 4,400,000 as consideration for the TUC APA (see Note 3). The promissory notes do not accrue interest and are payable upon demand at any time after October 31, 2023. The entire aggregate, unpaid principal sum of the note is immediately due and payable upon the occurrence of a change in control, as defined in the agreement. On March 5, 2024, the Company entered into the Superlatus SPA, whereby the Company sold its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On September 14, 2023, the Company issued a promissory note to Wellgisitcs (the “Wellgistics Note”) in the amount of $ 300,000 . The Company received a deposit of $ 200,000 on September 14, 2023, and an additional deposit of $ 100,000 on October 13, 2023. The Wellgisitcs Note accrues interest at 0 % per annum and is due and payable no later than 30 days after a change in control of borrower, as defined in the note agreement. As of December 31, 2023, the balance of the Wellgistics Note was $ 50,000 . The Wellgistics Note was fully paid off in February 2024. On June 16, 2023, the Company issued a secured debenture to Eat Well Investment Group, Inc. (the “Eat Well June 2023 Note”) in the amount of $ 1,150,000 for the purchase of Sapientia, a wholly-owned subsidiary of Superlatus. The Eat Well June 2023 Note is secured by 100 % of the membership interests in Sapientia. The Eat Well June 2023 Note began accruing interest at 12 % per annum, compounded monthly, as of October 31, 2023. The Eat Well June 2023 Note matured on December 31, 2023 . As of December 31, 2023, the balance of the Eat Well June 2023 Note was $ 1,150,000 . The Company has accrued interest of $ 23,063 as of December 31, 2023. On March 5, 2024, the Company entered into the Superlatus SPA, whereby the Company sold its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. On February 8, 2023, Sapientia, a wholly-owned subsidiary of Superlatus, entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well February 2023 Note”) in the amount of $ 25,000 . The Eat Well February 2023 Note is unsecured, accrues interest at a rate of 1.87 % per annum, and matures February 7, 2025 . As of December 31, 2023, the balance of the Eat Well February 2023 Note was $ 25,000 . The Company has accrued interest of $ 418 as of December 31, 2023. On March 5, 2024, the Company entered into the Superlatus SPA, whereby the Company sold its entire interest in Superlatus to Superlatus Foods, Inc. thereby transferring all assets and liabilities. 109 Table of Contents NOTE 11 – STOCKHOLDERS’ EQUITY Designation of Series X Preferred Stock On July 25, 2024, the Company revoked the authorization to issue shares of the Company’s Series A Preferred Stock, par value $ 0.00001 per share (the “Series A Preferred Stock”). Concurrently with revoking the Company’s authority to issue Series A Preferred Stock, the Company authorized the issuance of up to 9,211,246 shares of the Series X Preferred Stock, a new class of preferred stock. Holders of the Series X Preferred Stock are entitled to receive dividends on shares of the Series X Preferred Stock on an as-if-converted-to-Common-Stock basis, without regard to any beneficial ownership limitation described in a letter of transmittal, equal to and in the same form and manner as dividends are paid to holders of the shares of Common Stock. Subject to any requirements of the General Corporation Law of the State of Delaware, the Series X Preferred Stock has no voting rights. The Series X Preferred Stock ranks on parity with shares of Common Stock as to distributions of assets upon liquidation, dissolution, or winding up of the Company. As consideration for the Scienture Merger, at the Effective Time of First Merger, the shares of Scienture common stock issued and outstanding immediately prior to the Effective Time were converted into the right to receive, in the aggregate, (i) 291,536 shares of the Company’s common stock and (ii) 6,826,753 shares of the Company’s Series X Preferred Stock, each share of which is convertible into one share of common stock. On September 20, 2024, all previously issued shares of Series X Preferred Stock were converted into a total of 6,826,753 shares of common stock. Designation of Series C Preferred Stock Effective October 4, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series C Preferred Stock with the Secretary of the State of Delaware which designated 1,000 shares of the Company’s authorized and unissued preferred stock as convertible Series C Preferred Stock at a par value of $ 0.00001 per share. Hudson Global Ventures Stock Purchase Agreement On October 4, 2023, the Company entered into a Securities Purchase Agreement the “Hudson SPA”) with Hudson Global Ventures, LLC (“Hudson”). Under the terms of the Hudson SPA, the Company agreed to sell, and Hudson agreed to purchase, Two Hundred Ninety ( 290 ) shares of Series C Preferred Stock (the “Purchased Shares”) at a price of $ 1,000 per share and a Warrant to purchase up to 41,193 shares of Common Stock. Additionally, pursuant to the Agreement, 40,000 shares of Common Stock were issued to Hudson upon closing for a commitment fee. The Company received $ 250,000 in exchange for the Purchased Shares, Common Stock, and Warrants, net of issuance costs. On July 12, 2024, the Company converted 290 shares of Series C Preferred Stock into 52,158 shares of common stock at the election of the holder. Designation of Series B Preferred Stock Effective June 26, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of the Series B Preferred Stock with the Secretary of the State of Delaware which designated 787,754 shares of the Company’s authorized and unissued preferred stock as convertible Series B Preferred Stock at a par value of $ 0.00001 per share. 2023 1:15 Stock Split Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $ 1 . 110 Table of Contents Common Stock During the year ended December 31, 2024, the Company issued 490,698 shares of common stock for services. The fair value of shares issued for services was $ 4,598,294 and was included in general and administrative expenses in the consolidated statements of operations. During the year ended December 31, 2024, a warrant holder exercised a warrant and acquired 28,487 shares of common stock for $ 16,567 in proceeds (see Note 13). During the year ended December 31, 2024, an options holder exercised an option and acquired 2,371 shares of common stock for $ 9,840 in proceeds (see Note 14). On July 12, 2024, the Company converted 290 shares of Series C Preferred Stock into 52,158 shares of common stock at the election of the holder. On July 25, 2024, the Company issued 291,536 shares of common stock and 6,826,753 shares of Series X Preferred Stock pursuant to the Scienture Merger Agreement. The aggregate fair value of the purchase price consideration was $ 78,646,184 . In August 2024, the Company issued 28,571 shares of common stock pursuant to the exercise of warrants. On September 20, 2024, all previously issued shares of Series X Preferred Stock were converted into a total of 6,826,753 shares of common stock. Arena Note Commitment Shares As additional consideration for the Purchaser’s execution and delivery of this Agreement, (i) concurrently with the execution and delivery of this Agreement on the First Closing Date (as defined below), the Company shall cause the Transfer Agent, to issue to each Purchaser participating in the first Closing or its designee on the First Closing Date its pro rata portion of 55,000 of the shares of Common Stock being issued as Commitment Shares in connection with the First Closing, and (ii) in connection with any Closing following the First Closing, the Company shall cause its Transfer Agent to issue to each Purchaser participating in such Closing or its designee a certain number of Commitment Shares. The aggregate number of Commitment Shares owing to each Purchaser in connection with any Closing following the First Closing will be agreed among the Company and the Purchasers participating in such Closing, and shall be set forth in an allocation table prior to such Closing (each a “Commitment Shares Allocation Table.”) For the avoidance of doubt, all of the Commitment Shares issuable in connection with the First Closing on the First Closing Date shall be fully earned as of the First Closing Date regardless of whether a Subsequent Closing shall occur (see Note 10). In this connection, the Company issued to each Arena Investor participating in the First Closing its pro rata portion of 55,000 shares of the Company’s common stock. The fair value of shares issued was $ 420,200 was recognized as a debt discount, which was amortized to interest expense in full as commitment shares in connection with first closing was fully earned as of first closing date. Equity Line of Credit On November 25, 2024, the Company entered into a purchase agreement (“ELOC Agreement”) with Arena Business Solutions Global SPC II, Ltd (the “Investor”). Under the ELOC Agreement, the Company has the right, but not the obligation, to direct the Investor to purchase up to $ 50,000,000 in shares of the Company’s common stock (the “ELOC Shares”) upon satisfaction of certain terms and conditions contained in the ELOC Agreement, including, without limitation, and additional shares to be sold to the Investor from time to time under the ELOC Agreement. The term of the ELOC Agreement began on the date of execution and ends on the earlier of (i) the first day of the month following the 36-month anniversary of the execution date, (ii) the date on which the Investor shall have purchased the maximum amount of ELOC Shares, or (iii) the effective date of any written notice of termination delivered pursuant to the terms of the ELOC Agreement (the “Commitment Period”). 111 Table of Contents In consideration for the Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Investor, as a commitment fee: (i) 70,000 shares of the Company’s Common Stock (“Initial Commitment Fee Shares”) and (ii) in two separate tranches, a number of additional shares of common stock (“Additional Commitment Fee Shares” and, together with the Initial Commitment Fee Shares, the “Commitment Fee Shares”) equal to (a) with respect to the first tranche, 500,000 divided by the simple average of the daily VWAP of our common stock during the five (5) trading days immediately preceding the effectiveness of the initial registration statement on which the Commitment Fee Shares are registered (the “Effectiveness Date”) and (b) with respect to the second tranche, 500,000 divided by the simple average of the daily VWAP of our common stock during the five (5) trading days immediately preceding the two (2) month anniversary of the Effectiveness Date. The Additional Commitment Fee Shares shall be subject to a true-up after each issuance pursuant to the terms of the ELOC Agreement. In consideration for the Investor’s execution and delivery of the ELOC Agreement, the Company issued to the Investor, as a commitment fee, 70,000 shares of the Company’s common stock on November 25, 2024. The fair value of shares issued was $ 534,800 and was included in deferred offering costs in the consolidated balance sheets. Special Cash Dividend On March 6, 2024, the Company announced the declaration of a special cash dividend of eight dollars ($ 8.00 ) per share of common stock, payable to stockholders of record as of March 18, 2024, with the dividend being paid on March 22, 2024. The special dividend of $ 12,671,072 (in the aggregate) was paid using a portion of the proceeds from the closing of the sale of certain assets to MMS. On July 9, 2024, the Company announced the declaration of a special cash dividend of one dollar and fifty cents ($ 1.50 ) per share of common stock, payable to stockholders of record as of July 19, 2024, with the dividend being paid on July 22, 2024. The special dividend of $ 2,187,759 was paid using a portion of the proceeds received in May 2024 in connection with the sale of certain assets to MMS. Equity Compensation Awards Each independent member of the Company’s board of directors (the “Board”) is to receive an annual grant of restricted common stock of the Company equal to $ 55,000 in value on April 1st of each year (or such date thereafter as the awards are approved by the Board), and valued on such same date, based on the closing sales price on such date (or the first business day thereafter), which restricted stock awards will vest at the rate of 1/4th of such awards over the following four calendar quarters, subject to such directors continued service to the Company. Effective on August 13, 2023, the Board approved the issuance of 24,444 shares of common stock of the Company to each of Mr. Fell and Mr. Peterson (who each at the time of issuance were members of the Board) for services rendered to the Company during fiscal 2023, which shares were valued at $ 110,000 . The Board also approved the issuance of 14,056 shares of common stock of the Company to Jeff Newell (who, at the time of issuance was a member of the Board) for services rendered during fiscal 2023, which were valued at $ 63,250 based on the most recent close price of the Company’s common stock on the date approved by the Board. The shares vest at the rate of 1/4th of such shares immediately on the grant date, and 1/4th of such shares on each of October 1, 2023, January 1, 2024 and April 1, 2024, subject to each applicable independent director’s continued service to the Company on such dates. Additionally, the Board approved 10,000 shares with immediate vesting to each Board member to recognize the significant additional work for various financing, sales, acquisitions, operations restructuring. All of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”) and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements. The Company’s board of directors and stockholders approved an amendment to the Plan increasing the available shares under the Plan to 5,000,000 shares of the Common Stock as such common stock existed on July 24, 2024. 112 Table of Contents NOTE 12 – PREFUNDED AND PRIVATE PLACEMENT WARRANTS On October 4, 2022 the Company entered into a securities purchase agreement (the “2022 SPA”) with an institutional investor (the “Purchaser”) which provided for the sale and issuance by the Company of (i) the Company’s common stock, (ii) pre-funded warrants (the “Pre-Funded Warrants”) and (iii) warrants (the “Private Placement Warrants” and, together with the shares of common stock and the Pre-Funded Warrants, the “Securities”). On January 4, 2023, the investor exercised the Pre-Funded Warrants for a purchase price of $ 6.02 . The investor was issued the shares on this date. Each Private Placement Warrant has an exercise price of $ 22.50 per share and is exercisable following the stockholder approval obtained in December 2022, and will expire on the fifth anniversary of the date on which the Private Placement Warrants became exercisable. The Private Placement Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions, and include full ratchet anti-dilutive rights in the event the Company issues shares of Common Stock or Common Stock equivalents within fifteen months of the initial exercise date, with a value less than the then exercise price of such Private Placement Warrants, subject to certain customary exceptions, and further subject to a minimum exercise price of $ 3.48 per share. The Private Placement Warrants also include certain rights upon ‘fundamental transactions’ as described in the Private Placement Warrants, including allowing the holders thereof to require that the Company re-purchase such Private Placement Warrants at the Black Scholes Value of such securities. NOTE 13 – WARRANTS During the year ended December 31, 2024, 28,487 warrants to purchase shares of common stock were exercised for a total purchase price of $ 16,567 (see Note 11). In connection with a note (see Note 10), in August 2024 the Company issued 76,923 warrants to purchase common stock. The warrants have an exercise price of $ 9.36 per share, are immediately exercisable and have a term of 5 years. In August 2024, the holder exercised 28,571 warrants for shares of commons stock on a cashless basis. The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. Compensation cost related to the warrants for the year ended December 31, 2024, and 2023 was $ 71,332 and $ 0 , respectively. As of December 31, 2024 and 2023, the Company remeasured the fair value of warrants outstanding at $ 919,935 and 736,953 , respectively. In connection with remeasurement of warrants, a loss of $ 182,982 and $ 148,420 was recognized during the years ended December 31, 2024 and 2023, respectively, as the change in fair value of warrant liability. The Company’s outstanding and exercisable warrants, as of December 31, 2024 and 2023, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life In Years Intrinsic Value Warrants outstanding as of December 31, 2022 179,331 $ 22.50 4.72 $ 6,731 Warrants granted 41,193 7.20 4.76 - Warrants forfeited, expired, cancelled - - - - Warrants exercised ( 1,795 ) 0.90 - - Warrants outstanding as of December 31, 2023 218,729 19.62 3.95 - Warrants granted 76,923 9.36 - - Warrants forfeited, expired, cancelled - - - - Warrants exercised ( 57,058 ) 8.25 - - Warrants outstanding as of December 31, 2024 238,594 $ 19.02 3.20 $ - Warrants exercisable as of December 31, 2024 238,594 $ 19.02 3.20 $ - 113 Table of Contents NOTE 14 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 155,556 shares, and the Plan provides for automatic increases in the number of shares available under such plan (currently 133,333 shares) on April 1 st of each calendar year, beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. The administrator as a result of the annual meeting shareholder vote increased the number of shares available to grant to employees under the Plan by 2,000,000. The administrator did not approve an increase in the number of shares covered under the Plan as of April 1, 2022. The Company’s board of directors and stockholders approved an amendment to the Plan increasing the available shares under the Plan to 5,000,000 shares of the Common Stock as such common stock existed on July 24, 2024. For the year ended December 31, 2024, no options to purchase shares were granted. For the year ended December 31, 2024, 2,371 options to purchase shares of common stock were exercised for $ 9,840 in cash (see Note 12). Total compensation cost related to stock options granted was $ 25,584 and $ 29,738 for the years ended December 31, 2024, and 2023, respectively. The following table represents stock option activity for the years ended December 31, 2024 and 2023: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted-Average Exercise Price Weighted-Average Contractual Life in Years Intrinsic Value Options outstanding as of December 31, 2022 19,708 $ 66.00 3.92 $         - Options exercisable as of December 31, 2022 17,167 66.30 3.89 - Options granted 9,053 6.08 4.25 - Options forfeited ( 140 ) 82.33 1.75 - Options expired ( 2,392 ) 89.89 0.06 - Options exercised - - - - Options outstanding as of December 31, 2023 26,229 43.04 3.70 - Options exercisable as of December 31, 2023 16,141 60.75 3.64 - Options granted - - - - Options adjusted 72 - - - Options expired - - - - Options exercised ( 2,371 ) 53.29 2.82 - Options outstanding as of December 31, 2024 23,930 $ 42.16 2.73 $ - Options exercisable as of December 31, 2024 23,930 $ 42.16 1.83 $ - 114 Table of Contents NOTE 15 – CONTINGENCIES Exclusive License and Commercial Agreements Scienture entered into an exclusive license and commercial agreement with Kesin Pharma Corporation (“Kesin”) whereby Scienture granted the exclusive license rights to commercialize SCN-102 in 2022 and SCN-104 in 2023 to Kesin (SCN-102 and SCN-104 are together referred to as “the Products”) for use in the United States of America. In March 2024, the parties have terminated the agreement, and the parties agreed that Scienture shall pay Kesin a total gross amount of $ 1,285,000 upon commercialization of product via a royalty arrangement This agreement also requires that if the full $1,285,900 has not been repaid within two years of the early of i) commercial launch or ii) 120 from FDA approval, then interest will accrue prospectively at a rate of 8% annually on unpaid balance. Accordingly, Scienture recorded a $1,285,000 termination fee liability . As of September 30, 2024, the entire amount is outstanding. In August 2024, Kesin demanded immediate payment of the full amount under the Kesin Termination Agreement, alleging the full amount is payable in connection with the consummation Scienture LLC’s business combination with the Company. Scienture LLC has disputed that the amount is payable, and the parties entered into discussions to resolve the issue. On March 11, 2025, Kesin filed a complaint against Scienture LLC in the United States District Court for the Eastern District of New York seeking payment of the disputed $ 1.285 million. There can be no assurance that an amicable resolution will be obtained. Scienture LLC intends to vigorously defend itself in the litigation. NOTE 16 – LEASES The Company entered into a lease agreement for the period of October 2018 to November 2023. At inception, management had included the renewal period from November 2023 to November 2028 within the initial recognition of the related right of use assets and lease liabilities, as it was reasonably expected, at the time, that the renewal option would be exercised. The Company determined that the new lease required measurement and recognition of the lease liability and right-of-use assets of $ 313,301 . The lease is classified as an operating lease. No incentives were included in the lease. On July 25, 2024, the Company entered into and closed the Scienture Merger Agreement. Pursuant to the Scienture Merger Agreement, the Company acquired right of use asset value of $ 61,578 and right of use liability of $ 61,886 on the acquisition date together with all the assets and liabilities of Scienture. The table below reconciles the fixed component of the undiscounted cash flows for and the total remaining years to the lease liabilities recorded in the consolidated balance sheet as of December 31, 2024. SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Future lease obligations 2025 $ 83,538 2026 73,084 2027 56,919 2028 48,612 Total minimum lease payments 262,154 Less: effect of discounting ( 42,351 ) Present value of future minimum lease payments 219,803 Less: current obligation under lease 63,334 Long-term lease obligations $ 156,469 For the years ended December 31, 2024, and 2023, total operating lease expense was $ 82,342 and $ 323,961 , respectively, which is included in general and administrative expenses in the consolidated statements of operations, as well as $ 0 and $ 271,922 from discontinued operations, respectively. For the years ended December 31, 2024, and 2023, total short-term lease expense was $ 10,978 and $ 62,016 respectively, which is included in general and administrative expenses in the condensed consolidated statements of operations, as well as $ 750 and $ 34,000 from discontinued operations, respectively. 115 Table of Contents NOTE 17 – SEGMENT REPORTING Factors used to identify the Company’s reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company’s operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates all reporting segments in one geographical area (the United States). The Company’s CEO is the chief operating decision-maker. The Company classifies its business interests into reportable segments which are: ● Integra - Licensed wholesaler of brand, generic and non-drug products – B2B sales ● Scienture – pharmaceutical research company which is engaged in the research and development of branded pharmaceutical products ● Unallocated - Other – corporate overhead expense and discontinued operations. SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Year Ended December 31, 2024 Integra Scienture Unallocated Total Revenues $ 136,643 $ - $ - $ 136,643 Cost of Sales 130,638 - - 130,638 Gross Profit 6,005 - - 6,005 Profit/Loss ( 1,827,707 ) ( 3,509,597 ) 14,403,102 9,065,798 Interest expense - 231,639 1,103,992 1,335,631 Depreciation 2,000 - - 2,000 Total Assets $ 3,260,532 $ 98,072,001 $ 3,521,272 $ 104,853,805 Geographic information as of and for the year ended December 31, 2024 is presented below: SCHEDULE OF GEOGRAPHIC INFORMATION Revenues For The Year Ended December 31, 2024 Total Assets as of December 31, 2024 United States $ 136,643 $ 104,853,805 Year Ended December 31, 2023 Integra Scienture Unallocated Total Revenues $ 1,363,830 $ - $ - $ 1,363,830 Cost of Sales 1,314,800 - - 1,314,800 Gross Profit 49,030 - - 49,030 Profit/Loss ( 668,625 ) - ( 17,174,949 ) ( 17,843,574 ) Interest expense - - 1,143,223 1,143,223 Depreciation 2,000 - 17,375 19,375 Total Assets $ 220,634 $ - $ 12,312,279 $ 12,532,913 Geographic information as of and for the year ended December 31, 2023 is presented below: Revenues For The Year Ended December 31, 2023 Total Assets as of December 31, 2023 United States $ 1,363,830 $ 12,532,913 NOTE 18 – INCOME TAXES The provision (benefit) for income taxes on income from operations for the years ended December 31, 2024 and 2023 consists of the following: SCHEDULE OF PROVISION FOR INCOME TAXES 2024 2023 Federal: Current $ - $ - Deferred ( 534,396 ) - Federal total ( 534,396 ) - State Current - - Deferred - - State total - - Total $ ( 534,396 ) $ - During the year ended December 31, 2024, the Company recorded a $ 360,016 tax provision expense pertaining to discontinued operations, which is included within net income (loss) from discontinued operations, net of tax per the consolidated statements of operations. The accompanying income tax payable is included within accrued liabilities on the consolidated balance sheet. Income (loss) before income taxes for the years ended December 31, 2024 and 2023 consisted of the following: SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAXES 2024 2023 US $ 9,600,194 $ ( 17,843,574 ) 116 Table of Contents Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2024 2023 Deferred Tax Assets: Net operating losses $ 1,985,391 $ 5,800,214 Capitalized research and development costs 316,902 - Debt issuance costs 186,155 - Accruals and reserves 31,168 - Purchased intangibles - 151,877 Lease liability 9,008 127,896 Total Deferred tax assets 2,528,624 6,079,987 Deferred Tax Liabilities: Purchased goodwill - ( 15,534 ) Intangibles ( 16,044,000 ) - Right to use assets ( 8,838 ) ( 127,896 ) Total Deferred tax liabilities ( 16,052,838 ) ( 143,430 ) Valuation Allowance - 5,936,557 Net deferred tax asset (liability) $ ( 13,524,213 ) $ - For 2023, the Company has established a valuation allowance equal to the full amount of the deferred tax asset primarily due to uncertainty in the utilization of the net operating loss carry forwards. As of December 31, 2024, the Company utilized all remaining valuation allowance, resulting in a net deferred tax liability of $ 13,524,213 . The estimated net operating loss carry forwards of approximately $ 11,998,985 will be available based on the new carryover rules in section 172(a) passed with the Tax Cuts and Jobs Acts. NOTE 19 – SUBSEQUENT EVENTS In January 2025, the Company issued in aggregate 240,000 shares of common stock for services. Equity Line of Credit In connection with the ELOC Agreement (see Note 11), the investor purchased 2,800,000 shares of common stock for net proceeds of approximately $ 4.6 million during the calendar year beginning January 1, 2025. In addition, the Company issued the investor an additional 295,901 commitment fee shares as part of a true-up calculation. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers On March 13, 2025, the Board of Directors appointed Eric Sherb to serve as the Company’s Chief Financial Officer effective as of March 13, 2025 (the “Effective Date”). Mr. Sherb will succeed Prashant Patel, who previously served as the Company’s Interim Principal Financial/Accounting Officer. Mr. Patel notified the Company’s Board of Directors of his intention to resign his position as Interim Principal Financial/Accounting Officer effective as of the Effective Date. Mr. Patel will continue to serve as the Company’s President and Chief Operating Officer. Mr. Patel’s decision to resign as the Company’s Interim Principal Financial/Accounting Officer is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices. Director Resignations On January 15, 2025 and January 16, respectively, Narasimhan Mani and Prashant Patel each voluntarily resigned as directors of the Company. Neither resignation was the result of any dispute or disagreement with the Company or any matter relating to the Company’s operations, policies or practices. Mr. Patel and Dr. Mani will not receive compensation for their service on the Board of Directors of the Company during 2025. Mr. Patel and Dr. Mani each will continue on in their respective management roles. In connection with the foregoing director resignations, the Board approved a decrease in the size of the Board from 7 directors to 5 directors. As such, the Board currently does not have any vacancies. 117 Table of Contents ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None.